Skip Navigation

AIDSInfo logo

 
Home > Drugs > GS 9137 (elvitegravir)

GS 9137 (elvitegravir)
el-vy-TEH-gra-veer   Audio
Drug Class: Integrase Inhibitors
GS 9137 is a type of medicine called an integrase inhibitor. Integrase inhibitors work by blocking integrase, a protein that HIV needs to insert its viral genetic material into the genetic material of an infected cell.

HIV/AIDS-Related Uses
GS 9137 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the treatment of HIV infection. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

Dosage Form/Administration
GS 9137 is taken by mouth with food.

Recommended Daily Dose
Many dosages of GS 9137 have been studied. Once-daily dosages of 25, 50, and 125 mg will continue to be studied; all of these doses will be given by mouth with ritonavir 100 mg.

Contraindications
Individuals should tell a doctor about any medical problems before taking this medicine.

Possible Side Effects
Along with its desired effects, GS 9137 may cause some unwanted effects. Although not all of these effects are known, headache, loss of appetite, and elevated liver enzyme levels have been reported.

Drug and Food Interactions
A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.

Clinical Trials
Click here to search ClinicalTrials.gov for trials that use GS 9137 (elvitegravir).

Manufacturer Information
GS 9137 (elvitegravir)
  Gilead Sciences Inc
  333 Lakeside Dr
  Foster City,  CA  94404
  (800) 445-3235
    
Updated June 24, 2008